A citation-based method for searching scientific literature

Amber L Beitelshees, Bruce R Leslie, Simeon I Taylor. Diabetes 2019
Times Cited: 21







List of co-cited articles
75 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
42

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
42

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
33

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Vlado Perkovic, Meg J Jardine, Bruce Neal, Severine Bompoint, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull,[...]. N Engl J Med 2019
23

Effects of medical therapies on retinopathy progression in type 2 diabetes.
Emily Y Chew, Walter T Ambrosius, Matthew D Davis, Ronald P Danis, Sapna Gangaputra, Craig M Greven, Larry Hubbard, Barbara A Esser, James F Lovato, Letitia H Perdue,[...]. N Engl J Med 2010
787
19

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
Christoph Wanner, Silvio E Inzucchi, John M Lachin, David Fitchett, Maximilian von Eynatten, Michaela Mattheus, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Bernard Zinman. N Engl J Med 2016
19

Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors).
Mikhail Kosiborod, Matthew A Cavender, Alex Z Fu, John P Wilding, Kamlesh Khunti, Reinhard W Holl, Anna Norhammar, Kåre I Birkeland, Marit Eika Jørgensen, Marcus Thuresson,[...]. Circulation 2017
532
14

Canagliflozin inhibits interleukin-1β-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms.
Sarah J Mancini, Daria Boyd, Omar J Katwan, Anastasiya Strembitska, Tarek A Almabrouk, Simon Kennedy, Timothy M Palmer, Ian P Salt. Sci Rep 2018
123
14

An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus.
Daniel S Hsia, Owen Grove, William T Cefalu. Curr Opin Endocrinol Diabetes Obes 2017
147
14

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Steven P Marso, Stephen C Bain, Agostino Consoli, Freddy G Eliaschewitz, Esteban Jódar, Lawrence A Leiter, Ildiko Lingvay, Julio Rosenstock, Jochen Seufert, Mark L Warren,[...]. N Engl J Med 2016
14

10-year follow-up of intensive glucose control in type 2 diabetes.
Rury R Holman, Sanjoy K Paul, M Angelyn Bethel, David R Matthews, H Andrew W Neil. N Engl J Med 2008
14

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
14

Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials.
Yuliya Lytvyn, Petter Bjornstad, Jacob A Udell, Julie A Lovshin, David Z I Cherney. Circulation 2017
255
14


Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Inder S Anand, Jan Bělohlávek,[...]. N Engl J Med 2019
14

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
Milton Packer, Stefan D Anker, Javed Butler, Gerasimos Filippatos, Stuart J Pocock, Peter Carson, James Januzzi, Subodh Verma, Hiroyuki Tsutsui, Martina Brueckmann,[...]. N Engl J Med 2020
14


Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study.
Frederik Persson, Thomas Nyström, Marit E Jørgensen, Bendix Carstensen, Hanne L Gulseth, Marcus Thuresson, Peter Fenici, David Nathanson, Jan W Eriksson, Anna Norhammar,[...]. Diabetes Obes Metab 2018
133
9

Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes: A Meta-analysis.
Suetonia C Palmer, Dimitris Mavridis, Antonio Nicolucci, David W Johnson, Marcello Tonelli, Jonathan C Craig, Jasjot Maggo, Vanessa Gray, Giorgia De Berardis, Marinella Ruospo,[...]. JAMA 2016
247
9

Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study.
Peter Ueda, Henrik Svanström, Mads Melbye, Björn Eliasson, Ann-Marie Svensson, Stefan Franzén, Soffia Gudbjörnsdottir, Kristian Hveem, Christian Jonasson, Björn Pasternak. BMJ 2018
183
9

The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension.
Florian Gembardt, Christoph Bartaun, Natalia Jarzebska, Eric Mayoux, Vladimir T Todorov, Bernd Hohenstein, Christian Hugo. Am J Physiol Renal Physiol 2014
138
9

Biology of human sodium glucose transporters.
Ernest M Wright, Donald D F Loo, Bruce A Hirayama. Physiol Rev 2011
821
9


Natural Products as Sources of New Drugs from 1981 to 2014.
David J Newman, Gordon M Cragg. J Nat Prod 2016
9

Natural products as sources of new drugs over the period 1981-2002.
David J Newman, Gordon M Cragg, Kenneth M Snader. J Nat Prod 2003
9

Natural products as sources of new drugs over the last 25 years.
David J Newman, Gordon M Cragg. J Nat Prod 2007
9



Natural products in drug discovery and development.
G M Cragg, D J Newman, K M Snader. J Nat Prod 1997
688
9

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Silvio E Inzucchi, Richard M Bergenstal, John B Buse, Michaela Diamant, Ele Ferrannini, Michael Nauck, Anne L Peters, Apostolos Tsapas, Richard Wender, David R Matthews. Diabetes Care 2012
9


Phlorizin: a review.
Joel R L Ehrenkranz, Norman G Lewis, C Ronald Kahn, Jesse Roth. Diabetes Metab Res Rev 2005
556
9



GLP-1 receptor agonists: differentiation within the class.
Simeon I Taylor. Lancet Diabetes Endocrinol 2018
23
9

Cardiovascular outcome trials of diabetes drugs: lessons learned.
Simeon I Taylor, Bruce R Leslie. J Clin Invest 2018
8
25

Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.
David M Nathan, Patricia A Cleary, Jye-Yu C Backlund, Saul M Genuth, John M Lachin, Trevor J Orchard, Philip Raskin, Bernard Zinman. N Engl J Med 2005
9




Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes.
Ele Ferrannini, Simona Baldi, Silvia Frascerra, Brenno Astiarraga, Tim Heise, Roberto Bizzotto, Andrea Mari, Thomas R Pieber, Elza Muscelli. Diabetes 2016
364
9

Empagliflozin, an SGLT2 Inhibitor, Reduced the Mortality Rate after Acute Myocardial Infarction with Modification of Cardiac Metabolomes and Antioxidants in Diabetic Rats.
Hiroto Oshima, Takayuki Miki, Atsushi Kuno, Masashi Mizuno, Tatsuya Sato, Masaya Tanno, Toshiyuki Yano, Kei Nakata, Yukishige Kimura, Koki Abe,[...]. J Pharmacol Exp Ther 2019
57
9

CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
Ele Ferrannini, Michael Mark, Eric Mayoux. Diabetes Care 2016
599
9

How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial.
Silvio E Inzucchi, Bernard Zinman, David Fitchett, Christoph Wanner, Ele Ferrannini, Martin Schumacher, Claudia Schmoor, Kristin Ohneberg, Odd Erik Johansen, Jyothis T George,[...]. Diabetes Care 2018
412
9

SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
Faiez Zannad, João Pedro Ferreira, Stuart J Pocock, Stefan D Anker, Javed Butler, Gerasimos Filippatos, Martina Brueckmann, Anne Pernille Ofstad, Egon Pfarr, Waheed Jamal,[...]. Lancet 2020
481
9

Empagliflozin ameliorates endothelial dysfunction and suppresses atherogenesis in diabetic apolipoprotein E-deficient mice.
Byambasuren Ganbaatar, Daiju Fukuda, Masakazu Shinohara, Shusuke Yagi, Kenya Kusunose, Hirotsugu Yamada, Takeshi Soeki, Ken-Ichi Hirata, Masataka Sata. Eur J Pharmacol 2020
48
9

Dapagliflozin attenuates human vascular endothelial cell activation and induces vasorelaxation: A potential mechanism for inhibition of atherogenesis.
Tracey Gaspari, Iressa Spizzo, HongBin Liu, Yunshan Hu, Richard W Simpson, Robert E Widdop, Anthony E Dear. Diab Vasc Dis Res 2018
47
9

SGLT-2 (Sodium-Glucose Cotransporter 2) Inhibition Reduces Ang II (Angiotensin II)-Induced Dissecting Abdominal Aortic Aneurysm in ApoE (Apolipoprotein E) Knockout Mice.
Rebeca Ortega, Aida Collado, Francisca Selles, Herminia Gonzalez-Navarro, Maria-Jesus Sanz, José T Real, Laura Piqueras. Arterioscler Thromb Vasc Biol 2019
42
9




Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.